[1]
|
2020年全球癌症统计报告[J]. 中华预防医学杂志, 2021, 55(3): 398.
|
[2]
|
孙燕, 石远凯. 临床肿瘤内科手册[M]. 第5版. 北京: 人民卫生出版社, 2007: 11-21.
|
[3]
|
Han, C., Ye, S., Hu, C., Shen, L., Qin, Q., Bai, Y., et al. (2021) Clinical Activity and Safety of Penpulimab (Anti-PD-1) with Anlotinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: An Open-Label, Multicenter, Phase Ib/II Trial (AK105-203). Frontiers in Oncology, 11, Article 684867. https://doi.org/10.3389/fonc.2021.684867
|
[4]
|
Huang, Z., Pang, X., Zhong, T., Qu, T., Chen, N., Ma, S., et al. (2022) Penpulimab, an Fc-Engineered IgG1 Anti-PD-1 Antibody, with Improved Efficacy and Low Incidence of Immune-Related Adverse Events. Frontiers in Immunology, 13, Article 924542. https://doi.org/10.3389/fimmu.2022.924542
|
[5]
|
Dagher, O.K., Schwab, R.D., Brookens, S.K. and Posey, A.D. (2023) Advances in Cancer Immunotherapies. Cell, 186, 1814-1814.E1. https://doi.org/10.1016/j.cell.2023.02.039
|
[6]
|
Salmaninejad, A., Valilou, S.F., Shabgah, A.G., Aslani, S., Alimardani, M., Pasdar, A., et al. (2019) PD‐1/PD‐L1 Pathway: Basic Biology and Role in Cancer Immunotherapy. Journal of Cellular Physiology, 234, 16824-16837. https://doi.org/10.1002/jcp.28358
|
[7]
|
王思渊, 鲁辉, 杨纯. PD-1/PD-L1类单抗药物在肿瘤治疗中的应用进展[J]. 中国生物制品学杂志, 2023, 36(1): 105-111, 118.
|
[8]
|
陈洪丞成, 张宏权, 魏潇凡. PD-L1表达及其调控在肿瘤治疗中作用的研究进展[J]. 生理科学进展, 2023, 54(6): 526-532.
|
[9]
|
Sanmamed, M.F. and Chen, L. (2018) A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. Cell, 175, 313-326. https://doi.org/10.1016/j.cell.2018.09.035
|
[10]
|
Cheng, X., Veverka, V., Radhakrishnan, A., Waters, L.C., Muskett, F.W., Morgan, S.H., et al. (2013) Structure and Interactions of the Human Programmed Cell Death 1 Receptor. Journal of Biological Chemistry, 288, 11771-11785. https://doi.org/10.1074/jbc.m112.448126
|
[11]
|
赵喆, 唐彦, 朱惠娟, 等. 免疫检查点抑制剂引发的免疫相关不良反应研究进展[J]. 临床药物治疗杂志, 2022, 20(6): 1-6.
|
[12]
|
Lei, Q., Wang, D., Sun, K., Wang, L. and Zhang, Y. (2020) Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors. Frontiers in Cell and Developmental Biology, 8, Article 672. https://doi.org/10.3389/fcell.2020.00672
|
[13]
|
Morad, G., Helmink, B.A., Sharma, P. and Wargo, J.A. (2021) Hallmarks of Response, Resistance, and Toxicity to Immune Checkpoint Blockade. Cell, 184, 5309-5337. https://doi.org/10.1016/j.cell.2021.09.020
|
[14]
|
Dougan, M. (2020) Understanding and Overcoming the Inflammatory Toxicities of Immunotherapy. Cancer Immunology Research, 8, 1230-1235. https://doi.org/10.1158/2326-6066.cir-20-0372
|
[15]
|
Liu, Y., Zang, X., Wang, J., Huang, S., Xu, J. and Zhang, P. (2019) Diagnosis and Management of Immune Related Adverse Events (irAEs) in Cancer Immunotherapy. Biomedicine & Pharmacotherapy, 120, Article ID: 109437. https://doi.org/10.1016/j.biopha.2019.109437
|
[16]
|
Weber, J.S., Postow, M., Lao, C.D. and Schadendorf, D. (2016) Management of Adverse Events Following Treatment with Anti-Programmed Death-1 Agents. The Oncologist, 21, 1230-1240. https://doi.org/10.1634/theoncologist.2016-0055
|
[17]
|
Darnell, E.P., Mooradian, M.J., Baruch, E.N., Yilmaz, M. and Reynolds, K.L. (2020) Immune-related Adverse Events (irAEs): Diagnosis, Management, and Clinical Pearls. Current Oncology Reports, 22, Article No. 39. https://doi.org/10.1007/s11912-020-0897-9
|
[18]
|
张书培. PD-1/PD-L1抑制剂治疗所致免疫相关不良事件与晚期肿瘤患者疗效相关性研究[D]: [硕士学位论文]. 合肥: 安徽医科大学, 2022.
|
[19]
|
派安普利单抗注射液说明书[M]. 上海: 正大天晴康方(上海)生物医药科技有限公司, 2021.
|
[20]
|
Song, Y., Zhou, K., Jin, C., Qian, Z., Hou, M., Fan, L., et al. (2022) Penpulimab for Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter, Single-Arm, Pivotal Phase I/II Trial (AK105-201). Frontiers in Oncology, 12, Article 925236. https://doi.org/10.3389/fonc.2022.925236
|
[21]
|
Zhong, H., Sun, S., Chen, J., Wang, Z., Zhao, Y., Zhang, G., et al. (2024) First-Line Penpulimab Combined with Paclitaxel and Carboplatin for Metastatic Squamous Non-Small-Cell Lung Cancer in China (AK105-302): A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase 3 Clinical Trial. The Lancet Respiratory Medicine, 12, 355-365. https://doi.org/10.1016/s2213-2600(23)00431-9
|